Ann: Telstra Health soft launch HeraCARE, page-11

Mate, its still a specie.

So if you want to talk P/Es knock yourself out but that's not how species work.

If they scale this thing we are on. There are multiple avenues that are live to do that.

Whether they can execute to scale is the $50m dollar question. Ron got things rolling, lets see how Anoushka does.

Its still interesting, but lets see more licences (and even more trials).

Would dearly love to see the Directors buying on market.

A little confidence in their own ability to execute using their own dollars would go a long way towards me buying some more.